Literature DB >> 8015086

Complications of primary retroperitoneal lymph node dissection.

J Baniel1, R S Foster, R G Rowland, R Bihrle, J P Donohue.   

Abstract

The surgical morbidity in 478 patients who underwent primary retroperitoneal lymphadenectomy for clinical stages I and II nonseminomatous testicular cancer from 1982 to 1992 was reviewed. There were 54 complications in 51 patients (10.6%) and no operative related mortality. Superficial wound infection was the most frequent complication, comprising 45% of the total number of complications. Most major complications were related to small bowel obstruction and atelectasis. No complications caused permanent disability. The complication rate was less in patients who underwent a modified unilateral procedure (9.4%) than in those who underwent bilateral dissection (19.3%). Complications were significantly less with procedures done during the latter 6 years of the study (1987 to 1992). The ejaculation rate of patients undergoing a nerve sparing procedure was 98%, which reflects the increase in experience gained with the technique of nerve sparing modified unilateral dissection for early stage testicular cancer. This study reinforces the view that primary retroperitoneal lymph node dissection is an operation with minimal morbidity and no long-term effects. Furthermore, this study serves as the basis for cost-benefit and risk-benefit analyses of primary retroperitoneal lymph node dissection in low stage testicular cancer, which can be set against surveillance and primary chemotherapy programs.

Entities:  

Mesh:

Year:  1994        PMID: 8015086

Source DB:  PubMed          Journal:  J Urol        ISSN: 0022-5347            Impact factor:   7.450


  23 in total

Review 1.  Advances in the treatment of testicular cancer.

Authors:  Hans-Georg Kopp; Markus Kuczyk; Johannes Classen; Arnulf Stenzl; Lothar Kanz; Frank Mayer; Michael Bamberg; Jörg Thomas Hartmann
Journal:  Drugs       Date:  2006       Impact factor: 9.546

2.  Retroperitoneal lymph node dissection for high-risk stage I and stage IIA seminoma.

Authors:  Zaza Mezvrishvili; Laurent Managadze
Journal:  Int Urol Nephrol       Date:  2006       Impact factor: 2.370

3.  [Testicular tumor--yesterday--today--tomorrow].

Authors:  S Krege; C Wittekind; R Souchon; F Honecker; C Bokemeyer; P Albers; J Gschwend; H Rübben
Journal:  Urologe A       Date:  2006-09       Impact factor: 0.639

4.  [Testicular cancer--is there an indication for adjuvant or neoadjuvant systemic therapy?].

Authors:  S Langenkamp; P Albers
Journal:  Urologe A       Date:  2007-10       Impact factor: 0.639

Review 5.  Reducing morbidity of pelvic and retroperitoneal lymphadenectomy.

Authors:  Mark W Ball; Michael A Gorin; Mohamad E Allaf
Journal:  Curr Urol Rep       Date:  2013-10       Impact factor: 3.092

Review 6.  Critical evaluation of modified templates and current trends in retroperitoneal lymph node dissection.

Authors:  Shane Pearce; Zoe Steinberg; Scott Eggener
Journal:  Curr Urol Rep       Date:  2013-10       Impact factor: 3.092

Review 7.  [Retroperitoneal lymph node dissection in testis cancer].

Authors:  T Pottek
Journal:  Urologe A       Date:  2004-12       Impact factor: 0.639

Review 8.  Management of patients with low-stage nonseminomatous germ cell testicular cancer.

Authors:  Andrew J Stephenson; Joel Sheinfeld
Journal:  Curr Treat Options Oncol       Date:  2005-09

9.  [Results of the randomised phase III study of the German Testicular Cancer Study Group. Retroperitoneal lymphadenectomy versus one cycle BEP as adjuvant therapy for non-seminomatous testicular tumours in clinical stage I].

Authors:  M Hartmann; R Siener; S Krege; H Schmelz; K-P Dieckmann; A Heidenreich; P Kwasny; M Pechoel; J Lehmann; S Kliesch; K-U Köhrmann; R Fimmers; L Weissbach; V Loy; C Wittekind; P Albers
Journal:  Urologe A       Date:  2009-05       Impact factor: 0.639

10.  Management options for stage 1 nonseminomatous germ cell tumors of the testis.

Authors:  Stephen D W Beck
Journal:  Indian J Urol       Date:  2010 Jan-Mar
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.